Novo Nordisk Stock Price Forecast
Novo Nordisk (NYSE:NVO): Deep-Value Inflection as Weight-Loss Wars, Restructuring, and Tariff Shocks Collide
Stock Performance and Market Context
Novo Nordisk (NYSE:NVO) has entered one of the most volatile phases in its modern history. After a brutal twelve-month collapse of nearly 59% from its 52-week high of $120.56 to just $59.63 per share, the Danish pharmaceutical giant is now trading near multi-year valuation lows despite maintaining double-digit revenue growth and market-leading profitability. The current market capitalization sits around $263 billion, down from a peak above $640 billion in 2024, reflecting an enormous compression of investor sentiment after years of parabolic growth driven by its semaglutide portfolio —…
